Araris Biotech AG is pioneering the development of a novel, proprietary antibody-drug conjugate (ADC)-linker technology that enables payload attachment to ‘off-the-shelf’ antibodies in one step without needing to re-engineer or reduce antibodies
Araris Biotech AG is pioneering the development of a novel, proprietary antibody-drug conjugate (ADC)-linker technology that enables payload attachment to ‘off-the-shelf’ antibodies in one step without needing to re-engineer or reduce antibodies.